Shanghai Fudan Zhangjiang Bio Pharmaceutical : ADJUSTMENTS IN THE ROLES OF MEMBERS OF THE NOMINATION COMMITTEE

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ADJUSTMENTS IN THE ROLES OF MEMBERS OF THE

NOMINATION COMMITTEE

To improve internal control and corporate governance, on 25 March 2021, the sixth meeting of the seventh session of the board of directors (the ''Board'') of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (the ''Company'') reviewed and approved the adjustments in the roles of members of the nomination committee of the Company (the ''Nomination Committee'') pursuant to the requirements of domestic laws, regulations and the listing rules of the STAR Market of the Shanghai Stock Exchange. Details of the adjustments are set out as follows:

Name	Role before adjustments	Role after adjustments
Wang Hai Bo	chairman of the Nomination Committee	member of the Nomination Committee
Zhou Zhong Hui	member of the Nomination Committee	member of the Nomination Committee
Xu Qing	member of the Nomination Committee	chairman of the Nomination Committee

By order of the Board

Wang Hai Bo

Chairman

As at the date of this announcement, the Board comprises:

Mr. Wang Hai Bo (Executive Director)

Mr. Su Yong (Executive Director)

Mr. Zhao Da Jun (Executive Director)

Mr. Shen Bo (Non-executive Director)

Ms. Yu Xiao Yang (Non-executive Director)

Mr. Zhou Zhong Hui (Independent Non-executive Director)

Mr. Lam Yiu Kin (Independent Non-executive Director)

Mr. Xu Qing (Independent Non-executive Director)

Mr. Yang Chun Bao (Independent Non-executive Director)

Shanghai, the PRC

25 March 2021

* For identification purpose only.